# Neushen Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neushen-therapeutics

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.neushen.com
- Total disclosed funding: $80M
- Latest round: Series B (Sep 2, 2026)
- Investors on record: 11

## About

Based in Shanghai, China and founded in 2021, NeuShen Pharmaceutical (Shanghai) Co., Ltd., trading under the name NeuShen Therapeutics, provides central nervous system (CNS) drug development solutions for the healthcare industry. The company was established to address major unmet clinical needs in the central nervous system through a dual platform of AAV gene therapy and small molecule innovation. The firm currently provides preclinical and clinical research candidates for conditions such as schizophrenia and Alzheimer's disease to the global pharmaceutical market. The Founder and CEO is Dr. Huaqiong Shen, who previously served as CEO of Days of The Biotechnology.

In September 2026, Neushen Therapeutics raised over USD 80 million in Series B funding from B Capital, Legend Capital, MPCi, Hainan Zhenmai Private Equity Fund Management, Shanghai State-owned Capital Investment Leading Fund, Lilly Asia Ventures, and other investors.

Neushen Therapeutics focuses on the central nervous system (CNS) innovative drug development and has a dual platform for adenovirus-associated virus (AAV) gene therapy and small molecule drug therapy innovation, with AAV-based gene therapy and small molecule drug therapy innovation driving engine. AAV gene therapy platform enables the development of AAV-compatible microRNA scaffolds for effective and precise gene silencing.

The company’s revenue is generated through strategic partnerships and licensing agreements for its proprietary drug candidates, and by developing therapeutic assets for future global commercialization within the central nervous system market.

The company will primarily use the Series B funding to expand its innovative pipeline in the CNS field, accelerate the global clinical development of core projects, and explore breakthrough potential treatment pathways focusing on major unmet clinical needs worldwide.

## Funding rounds

- Series B, Sep 2, 2026, $80M — Legend Capital, Lilly Asia Ventures, B Capital, MPCi, Shanghai State-owned Capital Investment Leading Fund, Hainan Zhenmai Private Equity Fund Management
- Series A, Jan 28, 2026 — Lilly Asia Ventures, Lapam Capital, Pivotal Life Sciences, Shanghai Healthcare Capital, Together To Miracle
- Series A, Apr 18, 2025 — Lapam Capital, Guangzhou Cherami Sun Tour Equity Investment Management, Shanghai Healthcare Capital

## Investors

- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series A
- Guangzhou Cherami Sun Tour Equity Investment Management — Series A
- Shanghai Healthcare Capital (https://capitalatlas.ai/funds/shanghai-healthcare-capital) — Series A
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A, Series B
- Pivotal Life Sciences (https://capitalatlas.ai/funds/pivotal-life-sciences) — Series A
- Together To Miracle — Series A
- Legend Capital — Series B
- B Capital (https://capitalatlas.ai/funds/b-capital) — Series B
- MPCi (https://capitalatlas.ai/funds/mpci) — Series B
- Shanghai State-owned Capital Investment Leading Fund (https://capitalatlas.ai/funds/shanghai-state-owned-capital-investment-leading-fund) — Series B
- Hainan Zhenmai Private Equity Fund Management (https://capitalatlas.ai/funds/hainan-zhenmai-private-equity-fund-management) — Series B